San Francisco: A look at what’s new in gastric cancer (GC) from the 2017 ASCO GI meeting.
Day 1 of #GI17 is filling up…
There were several phase 3 trials presented in GC and gastro-esophageal junction (GEJ) carcinoma in both targeted therapies and immunotherapies this past weekend.
- When we look carefully at the latest data, what do we find?
- Where are the opportunities and challenges in this niche?
Another critical question that many observers will be interested in is…
Will BMS’s checkpoint inhibitor, nivolumab (Opdivo), overcome recent setbacks in lung cancer and make a mark in stomach cancer to challenge approved targeted therapies such as ramucirumab (Cyramza)?
To learn more, subscribers can log in or you can access the article via the blue button below…
The 2016 Congress of the European Society for Medical Oncology (ESMO) is fast approaching. It takes place next month from October 7th to 11th and we will be on site covering the meeting for Biotech Strategy Blog. We’re looking forward to a great meeting!
If you are sitting on the fence as to whether you should go to Copenhagen, then hopefully our series of Previews will help you decide.
Be warned that accommodation is in already in short supply and ESMO are now putting people up across the Oresund bridge in Malmo, Sweden.
The Congress App has a lot of useful information and is well worth downloading, if you haven’t done so already.
Last week many of the late breaking abstract (LBA) titles were announced, although there are still some placeholders. While we won’t know the actual late-breaking data until the meeting, the LBA titles offer insights into what will be presented in Copenhagen.
In the second in our ESMO 2016 Preview series, we’re highlighting the lung cancer late breakers that we’re looking forward to hearing, providing some background on why they may be of interest, and a look at how some of subset landscapes may be a-changing in the future.
Subscribers can login to learn more insights or you can purchase access below via the blue button…
Updated data are often presented at conferences and therefore the results can differ from the submitted abstracts, which are sometimes submitted as placeholders based on immature data cutoffs. That was certainly the case in several examples at the ASCO GI conference in San Francisco last weekend.
After Monday’s look at new developments in the lower GI tract, we now turn our attention today to the upper GI tract with a focus on oesophageal, gastric (stomach), and gastro-esophageal junction (GEJ) cancers.
Over the last five years we have seen new approvals for targeted therapies such as HER2+ gastric cancer and relapsed refarctory gastric cancers with a VEGF inhibitor. Will that trend continue over the next five years or will we see new approaches such as immunotherapy enter the market and dominate?
To learn more, subscribers can log-in or you can sign-up in the box below…
The 2014 ASCO Gastrointestinal (GI) Cancer Symposium takes place in San Francisco from Jan 16-18 and is the second meeting in this year’s oncology conference calendar. GI cancers include oesophageal, gastric, colorectal and pancreatic cancers, as well as hepatocarcinoma or HCC (liver).
You can follow any tweets from ASCO GI using the hashtag #GI14.
This year, the topics that most caught my eye in the program were pancreatic and gastric cancers.
This post provides insights on the key studies that looked interesting to me at this event, based on the schedule available. The abstracts will be available on January 14th and can be accessed here.
Companies mentioned: Celgene, Lilly, Roche/Genentech, Aduro Biotech
Drugs mentioned: Abraxane, Gemzar, ramucirumab, Avastin, Herceptin, GVAX
Whew, having just finished the American Society of Hematology (ASH) meeting, we run on to the breast cancer symposium in San Antonio (SABCS), making for a very busy week of data deluge! Our Post ASH analysis will also run concurrently for a few days.
There are also a number of interesting areas to look out for in terms of interesting breast cancer developments.
Premium subscribers can find out more about the following below:
Companies: Roche, GSK, AbbVie, AstraZeneca, Novartis, Lilly
Drugs: Herceptin, Avastin, Perjeta, Tykerb, veliparib, olaparib, BKM120, ramucirumab, PD-1, PD-L1
Here’s a quick preview of some of the landmark data emerging from this conference, some positive, some negative.